ShiraTronics has successfully implanted its Chronic Migraine System in six patients, a significant advancement in migraine treatment, marking a major step forward in the field of neuromodulation.

The implantation is part of the RELIEV-CM clinical study, a collaborative effort with Australian researchers.

This study involves a team of neurologists and pain management experts responsible for overseeing the study and collecting data.

It is designed to assess the ShiraTronics Chronic Migraine System’s performance and lays the groundwork for future research.

The fully implantable system has been designed for the head using a minimally invasive technique and is aimed at chronic migraine management.

ShiraTronics CEO Rob Binney said: “The achievement of this crucial milestone has validated all aspects of our procedure, system, and therapy settings. Notably, it is encouraging that all six patients who completed the trial procedure opted for the permanent implantation of the ShiraTronics system.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The system administers targeted electrical pulses to disrupt migraine pain signals. This fully implantable, programmable device represents a potential new treatment modality for both patients and physicians.

Australian clinical research organisation Cercare director Dr Matthew Green implanted the ShiraTronics Chronic Migraine System in the patients.

Green said: “With two successful implants completed at our centre, we are highly encouraged by the results. This technology introduces a new therapy option previously unavailable to patients and offers great hope where previously there was none for those grappling with chronic migraine.”

Chronic migraines affect approximately 2% of the population and involve intense headaches and other severe symptoms for at least 15 days each month, affecting patients’ quality of life. Current treatments are often insufficient, highlighting the need for innovative therapeutic options.

ShiraTronics’ system is specifically tailored to combat the debilitating effects of chronic migraines.